Abstract Background: Myeloproliferative neoplasms (MPN) are a group of malignant hematological disorders characterized by excessive proliferation of blood cells and are often accompanied by splenomegaly, thrombosis, and bleeding tendencies. The main subtypes of MPN include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The acquired somatic JAK2-V617F mutation occurs in approximately 95% of PV cases and in about 50% of ET or PMF patients. This mutation results in constitutive activation of the JAK2 kinase signaling pathway, establishing it as a critical therapeutic target in MPNs. Therefore, to enable preclinical evaluation of therapies targeting this mutation, we developed a novel Jak2-V617F knock-in mouse model. Method: Firstly, we generated Jak2-Flox-V617F mice by inserting the inverted exon 14 cassette (carrying the c.1849 GT, p. V617F mutation) flanked by antiparallel loxp sites into the endogenous Jak2 exon14 locus via ES cell-based gene targeting. These mice were then crossed with Vav1-Cre mice to obtain heterozygous Jak2-Flox-V617F/Vav1-Cre offspring (Jak2-V617F mice), in which Cre-mediated recombination induces Jak2-V617F expression specifically in the hematopoietic cells. The mutant mice were phenotyped using blood routine analysis, flow cytometry, H Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 970.
Yang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: